| Pharmaceutical active ingredients: |
| Potassium Canrenoate |
| Available forms, composition and doses of Spiroctan-M: |
| N / A |
| Spiroctan-M medical category: |
| Human:Aldosterone antagonists |
| Indications and usages, anatomical therapeutic chemical and diseases classification codes: |
| C03DA02 - Potassium Canrenoate |
| Pharmaceutical companies: manufacturers, researchers, developers, local distributors and suppliers: |
| Roche |
| Trade name |
Active ingredients |
Pharmaceutical company |
|
Spirocid | Acetarsol | Unidentified Pharmaceutical Company |
| Spiro-Co | Hydroflumethiazide; Spironolactone | H.N. Norton |
| Spirocort | Budesonide | AstraZeneca; Simesa |
| Spiroctan | Spironolactone | Roche; Biolab Sanus Farmaceutica; Ferlux Laboratoire; Leurquin Mediolanum Laboratoire |
| Spiroctanie | Spironolactone | Unidentified Pharmaceutical Company |
| Spiroctazine | Altizide; Spironolactone Micronized | Ferlux Laboratoire; Leurquin Mediolanum Laboratoire |
| Spiro-D | Furosemide; Spironolactone | Lichtenstein Pharmazeutica |
| Spiroderm | Spironolactone | Pfizer |
| Spirodigal | Beta-Acetyldigoxin; Spironolactone | Hormosan Pharma |
| Spiro-D-Tablinen | Furosemide; Spironolactone | Lichtenstein Pharmazeutica |